Enlivex develops Allocetra™, an off‑the‑shelf allogeneic cell therapy that reprograms macrophages to a homeostatic, anti‑inflammatory state, delivering significant pain reduction and functional improvement for patients with age‑related knee osteoarthritis. The therapy is manufactured as a cryopreserved product for rapid intravenous or intra‑articular administration and is supported by Phase II data showing a favorable safety profile in over 250 patients. Enlivex also backs its corporate treasury with a fee‑linked exposure to the Rain prediction‑markets protocol, aligning shareholder value with network activity.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Age-related knee osteoarthritis causes chronic pain, loss of joint function, and reduced independence for a growing elderly population, while existing treatments often provide limited relief and carry safety concerns.
Solution
Enlivex develops Allocetra™, an off‑the‑shelf allogeneic cell therapy that reprograms macrophages to a homeostatic, anti‑inflammatory state, addressing the underlying immune dysregulation in osteoarthritis. The therapy uses apoptotic mononuclear cells that present phosphatidylserine signals, prompting macrophage engulfment and restoration of immune balance. Clinical Phase II data show a 72 % reduction in pain and a 109 % improvement in joint function with a favorable safety profile across more than 250 treated patients. The product is manufactured through a streamlined, cryopreserved process, enabling rapid administration via intravenous infusion or intra‑articular injection without on‑site cell manipulation. Enlivex also backs its corporate treasury with a fee‑linked exposure to the Rain prediction‑markets protocol, aligning shareholder value with network activity rather than passive token holding.
Target Audience
Primary customers are healthcare providers and payers treating patients with age‑related knee osteoarthritis, as well as institutional investors seeking exposure to a combined biotech and decentralized finance asset.
Features
- Off‑the‑shelf allogeneic mononuclear cell product induced to a stable apoptotic state for immediate clinical use
- Macrophage homeostasis mechanism leveraging natural “eat‑me” phosphatidylserine signaling to induce anti‑inflammatory effects
- Flexible dosing options: systemic intravenous infusion or targeted intra‑articular injection
- Proven Phase II safety and efficacy: 72 % pain reduction, 109 % functional improvement in 250+ patients
- Scalable manufacturing process with cryogenic preservation, reducing cost and simplifying logistics
- Treasury strategy anchored in Rain prediction‑markets protocol on Arbitrum, with fee‑linked buyback mechanics tied to network activity